Wockhardt is a global pharmaceutical and biotech company employing over 10,000 people and 27 nationalities with presence in USA, UK, Ireland, Mexico, Russia and many other countries.
Through an announcement today, Wockhardt said it has received approval from the US health regulator for its generic Oxacillin injection used for the treatment of bacterial infections.
Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as urinary tract infections, respiratory tract infections, septicemia, wound infection, bacterial meningitis, etc.
The approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Oxacillin injections is for the strengths of 1 gm and 2 gm, Wockhardt said.
The company is expected to launch this product in the United States soon, it added.
“The product is being manufactured at a contract manufacturing facility, based near Milan, Italy,” Wockhardt officials said.
Wockhardt rose 1.04% to Rs 605.95 at 9:34 IST on BSE after the company said it received US drug regulator’s approval for antibiotic injection.
